Agile Therapeutics Inc. (NASDAQ:AGRX) was down 1.8% during trading on Tuesday . The company traded as low as $6.61 and last traded at $6.61, with a volume of 90,656 shares changing hands. The stock had previously closed at $6.73.

A number of equities research analysts recently commented on AGRX shares. Zacks Investment Research downgraded shares of Agile Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, March 29th. Cantor Fitzgerald reiterated a “buy” rating and set a $18.00 price target on shares of Agile Therapeutics in a research report on Tuesday, May 10th. FBR & Co reiterated a “buy” rating and set a $17.00 price target on shares of Agile Therapeutics in a research report on Tuesday, May 10th. Finally, Noble Financial reiterated a “buy” rating and set a $15.00 price target on shares of Agile Therapeutics in a research report on Friday, July 8th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $15.00.

The firm has a 50-day moving average price of $7.32 and a 200 day moving average price of $6.65. The firm’s market capitalization is $191.71 million.

Agile Therapeutics (NASDAQ:AGRX) last issued its quarterly earnings results on Monday, May 9th. The specialty pharmaceutical company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.11. Equities analysts predict that Agile Therapeutics Inc. will post ($1.08) earnings per share for the current year.

A hedge fund recently raised its stake in Agile Therapeutics stock. Marshall Wace LLP increased its position in shares of Agile Therapeutics Inc. (NASDAQ:AGRX) by 4.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 129,769 shares of the specialty pharmaceutical company’s stock after buying an additional 6,099 shares during the period. Marshall Wace LLP owned about 0.58% of Agile Therapeutics worth $1,267,000 at the end of the most recent reporting period.

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.